Many small-molecule compounds have been evaluated with potential antiproliferative activities. Ethyl 1-（phenylcarbamoyl）-2-（3,4,5-trimethoxyphenyl）cyclopropanecarboxylate, one novel cyclopropylamide analogue of co...Many small-molecule compounds have been evaluated with potential antiproliferative activities. Ethyl 1-（phenylcarbamoyl）-2-（3,4,5-trimethoxyphenyl）cyclopropanecarboxylate, one novel cyclopropylamide analogue of combretastatin-A4（CA-4）, has been synthesized and its crystal structure was characterized by X-ray single-crystal diffraction. The crystal belongs to monoclinic, space group P21/n, with a = 15.0263（3）, b = 7.6574（2）, c = 19.4117（4）, β = 111.9010（10）o, V = 2072.36（8）3, Z = 4, C22H24NO6, Mr = 398.42, Dc = 1.277 Mg/cm3, F（000） = 844, λ（MoKα） = 1.54178 , μ = 0.770 mm–1, R = 0.0546 and wR = 0.1889 for 3319 observed reflections（I 〉 2σ（I））. Meanwhile, the compound revealed potential antiproliferative activities in several cancer cells in vitro.展开更多
The crystal structure of the title compound（E）-N-（4-fluorobenzylidene）-3-（methylthio）-5-（3,4,5-trimethoxyphenyl）-4 H-1,2,4-triazol-4-amine（C_（19）H_（19）FN_4O_3S,Mr = 402.44） was synthesized,and its struct...The crystal structure of the title compound（E）-N-（4-fluorobenzylidene）-3-（methylthio）-5-（3,4,5-trimethoxyphenyl）-4 H-1,2,4-triazol-4-amine（C_（19）H_（19）FN_4O_3S,Mr = 402.44） was synthesized,and its structure was characterized by 1 H-NMR,13 C-NMR,ESI-MS and single-crystal X-ray diffraction.The crystal belongs to the triclinic system,space group P1 with a = 9.228（13）,b = 10.364（14）,c = 10.641（14） ？,α = 85.323（3）,β = 75.172（2）,γ = 80.903（3）°,μ = 0.20 mm^（-1）,M_r = 402.44,V = 970.64（10） ？~3,Z = 2,D_c = 1.377 g/cm^3,F（000） = 420,R = 0.0484 and wR = 0.1474 for 3181 observed reflections with I 〉 2σ（I）.In addition,the preliminary bioassay indicated that the title compound 5 exhibits better inhibitory activity against Hela than 5-fluorouracil.展开更多
文摘Many small-molecule compounds have been evaluated with potential antiproliferative activities. Ethyl 1-（phenylcarbamoyl）-2-（3,4,5-trimethoxyphenyl）cyclopropanecarboxylate, one novel cyclopropylamide analogue of combretastatin-A4（CA-4）, has been synthesized and its crystal structure was characterized by X-ray single-crystal diffraction. The crystal belongs to monoclinic, space group P21/n, with a = 15.0263（3）, b = 7.6574（2）, c = 19.4117（4）, β = 111.9010（10）o, V = 2072.36（8）3, Z = 4, C22H24NO6, Mr = 398.42, Dc = 1.277 Mg/cm3, F（000） = 844, λ（MoKα） = 1.54178 , μ = 0.770 mm–1, R = 0.0546 and wR = 0.1889 for 3319 observed reflections（I 〉 2σ（I））. Meanwhile, the compound revealed potential antiproliferative activities in several cancer cells in vitro.
基金supported by the National Natural Science Foundation of China(N0.21372113)the Guangzhou Science and Technology Project(No.201707010198)
文摘The crystal structure of the title compound（E）-N-（4-fluorobenzylidene）-3-（methylthio）-5-（3,4,5-trimethoxyphenyl）-4 H-1,2,4-triazol-4-amine（C_（19）H_（19）FN_4O_3S,Mr = 402.44） was synthesized,and its structure was characterized by 1 H-NMR,13 C-NMR,ESI-MS and single-crystal X-ray diffraction.The crystal belongs to the triclinic system,space group P1 with a = 9.228（13）,b = 10.364（14）,c = 10.641（14） ？,α = 85.323（3）,β = 75.172（2）,γ = 80.903（3）°,μ = 0.20 mm^（-1）,M_r = 402.44,V = 970.64（10） ？~3,Z = 2,D_c = 1.377 g/cm^3,F（000） = 420,R = 0.0484 and wR = 0.1474 for 3181 observed reflections with I 〉 2σ（I）.In addition,the preliminary bioassay indicated that the title compound 5 exhibits better inhibitory activity against Hela than 5-fluorouracil.
